SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases.
J A Crouzen, A L Petoukhova, M L D Broekman...
https://pubmed.ncbi.nlm.nih.gov/36964529/Actively Recruiting
Led by Haaglanden Medical Centre · Updated on 2024-03-12
130
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating a new method of stereotactic radiotherapy for treating brain metastases in this randomized phase II trial. The study compares the current standard stereotactic radiotherapy SRT delivered in one or three doses with a fractionated approach fSRT given in five doses. The goal is to find a potentially safer treatment that reduces long-term side effects like brain necrosis, which affects up to 40% of patients depending on tumor size and radiation dose. One group of participants will receive SRT in one or three sessions with doses ranging from 8 Gy up to 15-24 Gy. The other group will receive fSRT spread over five sessions with doses of 7 Gy up to 35 Gy, or for brain stem metastases, five sessions of 6 Gy up to 30 Gy. This treatment phase compares these two radiation schedules to assess differences in safety and tumor control. Participants will be monitored for survival, side effects, and quality of life for two years after treatment. Researchers will track the occurrence of brain necrosis or tumor recurrence, need for additional treatments, brain recurrences, corticosteroid and anti-epileptic drug use, and any grade 2 or higher toxicities. This thorough follow-up includes patient-reported outcomes and medical assessments to understand the treatments impact over time.
CONDITIONS
Improving Therapeutic Ratio With Hypo Fractionated Stereotactic Radiotherapy for Brain Metastases
J
Jaap D Zindler, MD, PhD
M
Mirjam Mast, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Haaglanden Medical Centre
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants receive stereotactic radiotherapy either as one or three fractions or hypo fractionated radiotherapy in five fractions to treat brain metastases.
1 to 5 visits depending on assigned treatment fractionation
Duration - Up to 2 years
Participants are monitored for survival, toxicity, brain tumor recurrence, and quality of life up to 2 years after treatment.
Regular visits throughout 2 years post-treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
J A Crouzen, A L Petoukhova, M L D Broekman...
https://pubmed.ncbi.nlm.nih.gov/36964529/Haaglanden Medical Centre
Lead Sponsor